Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer’s Disease
Main Article Content
ABSTRACT
Trace metals play an important role in the pathophysiology of amyloid precursor protein, amyloid beta, and tau, the key molecules involved in Alzheimer’s disease. Altering trace metal concentrations in the brain has been explored as a therapeutic strategy for Alzheimer’s disease. It is not only the accumulation of metals that drives amyloid beta aggregation, but also the lack of sufficient trace metals for other biological processes created through sequestration by amyloid beta that affects brain health and function. Thus, balancing metal levels to achieve therapeutic effects is an intricate process. This chapter summarizes the role of trace metals in Alzheimer’s disease and highlights the preclinical and clinical studies targeting metal homeostasis in animal models and humans. It further discusses recent developments in pharmacological approaches targeting metals in Alzheimer’s disease and provides an outlook on possible future treatments based on current translational research, for example, nanomedicine.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.